TY - JOUR
T1 - Inhibition of dengue virus RNA synthesis by an adenosine nucleoside
AU - Chen, Yen Liang
AU - Yin, Zheng
AU - Duraiswamy, Jeyaraj
AU - Schul, Wouter
AU - Lim, Chin Chin
AU - Liu, Boping
AU - Xu, Hao Ying
AU - Qing, Min
AU - Yip, Andy
AU - Wang, Gang
AU - Chan, Wai Ling
AU - Tan, Hui Pen
AU - Lo, Melissa
AU - Liung, Sarah
AU - Kondreddi, Ravinder Reddy
AU - Rao, Ranga
AU - Gu, Helen
AU - He, Handan
AU - Keller, Thomas H.
AU - Shi, Pei Yong
PY - 2010/7
Y1 - 2010/7
N2 - We recently reported that (2R,3R,4R,5R)-2-(4-amino-pyrrolo[2,3-d]pyrimidin- 7-yl)-3-ethynyl-5-hydroxymethyl-tetrahydro-furan-3,4-diol is a potent inhibitor of dengue virus (DENV), with 50% effective concentration (EC50) and cytotoxic concentration (CC50) values of 0.7 μM and >100 μM, respectively. Here we describe the synthesis, structure-activity relationship, and antiviral characterization of the inhibitor. In an AG129 mouse model, a single-dose treatment of DENV-infected mice with the compound suppressed peak viremia and completely prevented death. Mode-of-action analysis using a DENV replicon indicated that the compound blocks viral RNA synthesis. Recombinant adenosine kinase could convert the compound to a monophosphate form. Suppression of host adenosine kinase, using a specific inhibitor (iodotubercidin) or small interfering RNA (siRNA), abolished or reduced the compound's antiviral activity in cell culture. Studies of rats showed that 14C-labeled compound was converted to mono-, di-, and triphosphate metabolites in vivo. Collectively, the results suggest that this adenosine inhibitor is phosphorylated to an active (triphosphate) form which functions as a chain terminator for viral RNA synthesis.
AB - We recently reported that (2R,3R,4R,5R)-2-(4-amino-pyrrolo[2,3-d]pyrimidin- 7-yl)-3-ethynyl-5-hydroxymethyl-tetrahydro-furan-3,4-diol is a potent inhibitor of dengue virus (DENV), with 50% effective concentration (EC50) and cytotoxic concentration (CC50) values of 0.7 μM and >100 μM, respectively. Here we describe the synthesis, structure-activity relationship, and antiviral characterization of the inhibitor. In an AG129 mouse model, a single-dose treatment of DENV-infected mice with the compound suppressed peak viremia and completely prevented death. Mode-of-action analysis using a DENV replicon indicated that the compound blocks viral RNA synthesis. Recombinant adenosine kinase could convert the compound to a monophosphate form. Suppression of host adenosine kinase, using a specific inhibitor (iodotubercidin) or small interfering RNA (siRNA), abolished or reduced the compound's antiviral activity in cell culture. Studies of rats showed that 14C-labeled compound was converted to mono-, di-, and triphosphate metabolites in vivo. Collectively, the results suggest that this adenosine inhibitor is phosphorylated to an active (triphosphate) form which functions as a chain terminator for viral RNA synthesis.
UR - http://www.scopus.com/inward/record.url?scp=77953742065&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953742065&partnerID=8YFLogxK
U2 - 10.1128/AAC.00140-10
DO - 10.1128/AAC.00140-10
M3 - Article
C2 - 20457821
AN - SCOPUS:77953742065
SN - 0066-4804
VL - 54
SP - 2932
EP - 2939
JO - Antimicrobial agents and chemotherapy
JF - Antimicrobial agents and chemotherapy
IS - 7
ER -